Management of acquired Haemophilia A: A case series
S. Varvello1, M. Scandella2, G. Gargiulo2, B. Montaruli3, B. Parola4, G. N. Saglio1, P....
Read More
Category: VILLA DURAZZO PALLAVICINI 6sept
Immune Tolerance Induction with Nuwiq® (Simoctocog Alfa) in Nine Patients with Severe Haemophilia A and Inhibitors to FVIII
Ri J Liesner1, Alice Wilkinson2, Mary Mathias1, Neha Bhatnagar2, Tina Biss2, Georgina W...
Read More
Combination of emicizumab with simoctocog alfa for prophylaxis in previously untreated/minimally treated hemophilia A patients, and for managing inhibitor patients
Robert Sidonio1, Shannon Meeks1, Amy Shapiro2, Marilyn Manco-Johnson3 and Michael Callaghan41Emory...
Read More
The combination of plasma-derived FVIII/VWF with emicizumab has non-additive effects on thrombin generation assay independently of the presence of inhibitors in hemophilia A plasma
Maria Isabel Bravo1, Aida Raventos1, Alba Perez1, Montserrat Costa1, Todd Willis21Discovery...
Read More
Population pharmacokinetic model for recombinant factor VIII Fc fusion protein (rFVIIIFc) validated and optimized for use in children
L.H. Bukkems1*, J.M. Heijdra2*, M. Mathias3, P.W. Collins4, C.R.M. Hay5, R.C. Tait6, S. Mangles7,...
Read More
Final results from the NuProtect study of Nuwiq® (simoctocog alfa) treatment in previously untreated patients with severe haemophilia A
R.J. Liesner1, M. Jansen2, S. Knaub31Great Ormond Hospital for Children NHS Trust Haemophilia...
Read More